Mandate

Vinge advises Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood

May 22, 2025 M&A

Vinge has advised Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood Grupp OÜ (“Combiwood”).

Combiwood is one of Estonia’s leading woodworking groups, employing approximately 900 people and generating annual revenues of around EUR 210 million. The group operates several timber processing facilities across Estonia. AS Toftan is a well-established player in the timber industry and will continue to operate under its current name and brand, with Martin Arula remaining as CEO. The acquisition is expected to support the companies' long-term growth and support continued investment in sustainable wood processing. Together, the two companies will have combined revenues of approximately EUR 276 million and around 990 employees. The sale of AS Toftan is subject to approval by the competent competition authority.

Vinge’s team primarily consisted of Jonas Johansson, Johan Winnerblad, Egil Svensson and Olof Löfvenberg (M&A), and Jessica Öijer (Transaction Support Coordinator).

Read the client’s press release here 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025